2-[2-(3-Chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole

CAS: 1613695-14-9

Ref. 3D-NPC69514

Información del producto

• Nombre: 2-[2-(3-Chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole
• Marca: Biosynth
• Descripción: 2-[2-(3-Chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole (DCPI) is a cancer drug that inhibits the activity of DNA topoisomerase II. It is used to treat cancers that are resistant to other cancer drugs. DCPI is a potent inhibitor of DNA topoisomerase II and has been shown to be effective in treating multiple myeloma and acute lymphoblastic leukemia. DCPI binds to the active site of DNA topoisomerase II and prevents its cleavage of dsDNA, which leads to cell death by preventing the synthesis of proteins essential for cell division.

Propiedades químicas

• Peso molecular: 509.05 g/mol
• Fórmula: C₂₈H₃₃ClN₄O₃
• Pureza: Min. 95%